Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?

Hims & Hers Health (HIMS) shares tumbled over 30% after Novo Nordisk, maker of Wegovy, terminated their sales partnership, citing Hims & Hers' continued sale of compounded semaglutide. Novo Nordisk alleges this practice circumvents its patent protections and involves potentially unsafe products, despite the official drug shortage ending. This development introduces significant brand and litigation risk for Hims & Hers, impacting a segment contributing approximately 30% to its projected 2025 revenue, and raises questions about the company's future growth trajectory.

Analysis

Hims & Hers Health (HIMS) faces a significant operational and reputational crisis following the termination of its sales partnership with Novo Nordisk. The immediate catalyst was HIMS's continued sale of compounded semaglutide, the active ingredient in Novo Nordisk's patented drug Wegovy, even after the official drug shortage ended. This conflict has resulted in a sharp 30% decline in HIMS's stock price. The financial implications are material, as weight-loss drugs are projected to constitute approximately 30% of HIMS's 2025 revenue guidance of $2.3 billion to $2.4 billion. Novo Nordisk has escalated the dispute with serious allegations, including deceptive marketing, illegal mass compounding to circumvent patent law, and the use of potentially unsafe ingredients from unregulated manufacturers. While HIMS's core business demonstrated strong fundamentals prior to this, with subscriber growth from 391,000 in Q1 2021 to 1.7 million in Q1 2024, the current situation introduces substantial litigation risk and the potential for severe brand damage, transforming what was a high-growth story into a high-risk investment proposition.

Key Decisions for Investors

• Investors should re-evaluate Hims & Hers' risk profile, recognizing that the dispute introduces material litigation and reputational threats that could impair the 30% of revenue tied to its weight-loss segment.
• Monitor for any formal legal proceedings initiated by Novo Nordisk, as a lawsuit would likely create a significant and prolonged overhang on the stock's performance.
• Scrutinize future earnings reports for signs of contagion, specifically looking for any deceleration in subscriber growth or brand erosion in the company's core business segments outside of weight loss.
• Given the stock is still up nearly 100% over the past year despite the recent 30% drop, it may be prudent to consider trimming positions to manage risk until there is greater clarity on the legal and consumer-trust outcomes.